<DOC>
	<DOCNO>NCT02812251</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability JNJ-61393215 versus placebo single oral dose administration fast ( ascend dose level ) feed condition , characterize pharmacokinetics JNJ-61393125 plasma , cerebrospinal fluid ( CSF ) urine single oral dose administration investigate effect food ( high fat/high calorie ) pharmacokinetics JNJ-61393215 follow single oral dose administration .</brief_summary>
	<brief_title>Study Investigate Safety Tolerability , Pharmacokinetics Pharmacodynamics JNJ-61393215 Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Participants must body mass index ( BMI ) 18 30 kilogram per meter square kg/m^2 , inclusive ( BMI = weight/height^2 ) Participant must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform Screening admission clinical unit . Minor abnormality ECG , consider clinical significance investigator , acceptable . The presence Left Bundle Branch Block ( LBBB ) , Atrioventricular ( AV ) Block ( second degree high ) , permanent pacemaker implantable cardioverter defibrillator [ ICD ] lead exclusion Participants must healthy basis clinical laboratory test perform screen . If result serum chemistry panel , hematology urinalysis outside normal reference range , subject may include investigator judge abnormality clinically significant A man sexually active woman childbearing potential vasectomy must agree use barrier method birth control example , either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository study 3 month receive last dose study drug . All men must also donate sperm study 3 month receive last dose study drug . In addition , female partner also use appropriate method birth control least duration . Healthy male participant 18 54 year age , inclusive Part 1 3 Healthy male female participant 55 75 year age , inclusive Part 2 Participant history current liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic ( include coagulation disorder ) , rheumatologic , psychiatric , metabolic disturbance , inflammatory illness illness . Minor deviation , consider clinical significance investigator Janssen Safety Responsible Physician , acceptable Participant estimate glomerular filtration rate ( eGFR ) less ( &lt; ) 60 milliliter per minute per 1.73 meter square ( mL/min/1.73m^2 ) Screening Participant heart rate le ( &lt; ) 50 beat per minute ( bpm ) Screening admission clinical unit Participant history hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( antiHCV ) positive , clinically active liver disease , test positive HBsAg antiHCV Screening Participant Left Bundle Branch Block ( LBBB ) , Atrioventricular ( AV ) Block ( second degree high ) , permanent pacemaker implantable cardioverter defibrillator [ ICD ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>